Current concepts on the molecular biology of osteosarcoma

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 467-478

  Gorlick, Richard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19D12; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; BLOOM SYNDROME HELICASE; BORTEZOMIB; CEDIRANIB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLINIC ACID; GLYCOPROTEIN P; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 19D12; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; PARATHYROID HORMONE; PROTEIN FOS; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN; RECQ HELICASE; RETINOBLASTOMA PROTEIN; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; WERNER SYNDROME PROTEIN;

CANCER SURVIVAL; CARCINOGENESIS; CELL TYPE; CLINICAL FEATURE; CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG RESEARCH; DRUG SCREENING; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; HEREDITY; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; PAGET BONE DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RETINOBLASTOMA; ROTHMUND THOMSON SYNDROME; TISSUE DIFFERENTIATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; WERNER SYNDROME; BONE NEOPLASMS; GENETICS; MORTALITY;

BONE NEOPLASMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR BIOLOGY; OSTEOSARCOMA;

EID: 77953666099     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_27     Document Type: Conference Paper

References (55)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203-210.
2. Huvos A. Bone Tumors: Diagnosis, Treatment and Prognosis. 2nd ed. WB Saunders: Philadelphia; 1991.
3. Gorlick R, Bernstein ML, Toretsky JA, et al. Bone Tumours. In: Holland J, Frei E, eds. Cancer Medicine. 7th ed. Hamilton, ON: BC Decker; 2006:2019-2027.
4. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin N Am. 1997;44:973-989.
5. Ladanyi M, Gorlick R. The molecular pathology and pharmacology of osteosarcoma. Pediatr Pathol Mol Med. 2000;19:391-413.
6. Man T-K, Lu X-Y, Jaeweon K, et al. Genome-wide array comparative genomic hybridization reveals distinct amplifications in osteosarcoma. BMC Cancer. 2004;4:45.
7. Lau CC, Harris CP, Lu X-Y, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcomas. Genes Chromosomes Cancer. 2004;39:11-21.
8. Bayani J, Zielenska M, Pandita A, et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer. 2003;36:7-16.
9. Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumorsuppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 1998;63:817-824.
10. Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278:1262-1267.
11. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671.
12. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994;54:3042-3048.
13. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 1999;84:489-493.
14. Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A. 1985;82:6216-6220.
15. Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001;119:1699-1704.
16. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362.
17. Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.
18. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate. Cancer. 1997;79:1541-1547.
19. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925-930.
20. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003;95:669-674.
21. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111:367-372.
22. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev. 1996;5:239-246.
23. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1-7.
24. Grigoriadis AE, Schellander K, Wang ZW, Wagner ER. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol. 1993;122:685-701.
25. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102-104.
26. Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer. 2007;109:1870-1876.
27. Knowles BB, McCarrick J, Fox N, Solter D, Damjanov I. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol. 1990;137:259-262.
28. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
29. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-468.
30. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-877.
31. Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer. 1999;80:581-588.
32. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21-27.
33. Ferracini R, Renzo MFD, Scotlandi K, et al. The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or autocrine circuit. Oncogene. 1995;10:739-749.
34. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.
35. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572-577.
36. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of her-4 in primary osteosarcoma. Cancer Res. 2004;64:2047-2053.
37. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005;28:755-760.
38. Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer. 2007;121:943-954.
39. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112(10):2119-2129.
40. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in highgrade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333:380-1385.
41. Schwartz CL, Gorlick R, Teot L, et al. Multiple Drug Resistance in Osteogenic Sarcoma (INT0133). J Clin Oncol. 2007;25:2057-2062.
42. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999;5:621-627.
43. Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res. 2003;9:837-844.
44. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapyresistant pediatric osteosarcoma. Cancer Res. 2005;65:1748-1754.
45. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer. 2007;49:928-940.
46. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32-40.
47. Maris JM, Courtright J, Houghton PJ, et al. Initial Testing (Stage 1) of the VEGFR Inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50:581-587.
48. Tajbakhsh M, Houghton PJ, Morton CL, et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:992-1000.
49. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:799-805.
50. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2000;50:1198-1206.
51. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1181-1189.
52. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(6):1190-1197.
53. Hernan C, Morton CL, Houghton PJ, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the topoisopmerase I inhibitor topotecan. Proc AACR. 2008;710:710. [abstract].
54. Houghton PJ, Morton CL, Maris JM, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. Proc AACR. 2008;49:710. [abstract].
55. Smith MA, Morton CL, Maris JM, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the MEK 1/2 inhibitor AZD6244 (ARRY-142886). Proc AACR. 2008;49:710. [abstract].